LOS ANGELES, CA--(Marketwire - November 12, 2007) - HemaCare Corporation (OTCBB: HEMA) today announced that third quarter 2007 operations resulted in a net loss of $5,596,000, or $0.64 per share basic and diluted, compared to net income of $448,000, or $0.05 per share basic and diluted, for the same period of 2006. Included in the net loss for the quarter are a $4,259,000 non-cash charge for goodwill impairment associated with HemaCare BioScience, Inc. (“HemaBio”), the Company’s Florida-based research blood products operation, a $622,000 non-cash charge from the increase in the Company’s deferred tax asset valuation reserve to 100%, and a $290,000 operating loss at HemaBio, which the Company closed on November 5, 2007. The Company generated $9.6 million in revenue during the quarter, up 4% from $9.2 million reported for the third quarter of 2006.
